X0609 4 2026-10-02 0 0000886163 LIGAND PHARMACEUTICALS INC LGND 0001950232 Reardon Andrew false 555 HERITAGE DRIVE SUITE 200 JUPITER FL 33458 0 1 0 0 CLO & Secretary 1 Common Stock 2026-10-02 4 M 0 340 52.27 A 36854 D Common Stock 2026-10-02 4 S 0 833 302.5107 D 36021 D Common Stock 2026-10-02 4 S 0 1976 303.5444 D 34045 D Common Stock 2026-10-02 4 S 0 1535 304.5154 D 32510 D Common Stock 2026-10-02 4 S 0 404 306.1834 D 32106 D Common Stock 2026-10-02 4 S 0 235 307.1911 D 31871 D Common Stock 2026-10-02 4 S 0 17 307.74 D 31854 D Employee Stock Option (right to buy) 52.27 2026-10-02 4 M 0 340 0 D 2032-08-01 Common Stock 340 29104 D The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $302.14 to $303.06. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $303.14 to $304.12. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $304.19 to $305.01. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $305.71 to $306.46. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $306.72 to $307.54. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter. /s/Andrew Reardon 2026-10-06